Blank Andrew Scott
Known title: DirectorCIK: 0001789894
Blank Andrew Scott's purchase track record
How the stock did after each of Blank Andrew Scott's open-market purchases, measured from the purchase date. Several fills within a week count as one purchase.
Purchases measured
3
of 3 since April 23, 2025
Stock higher 6 months later
33%
3 months: 67%
Median 6-month return
-21.5%
3 months: +9.5%
Beat the S&P 500
33%
median -46.1% vs. index
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 9/19/2025 | BCDA | $360K | +9.5% | +3.5% | -2.4% |
| 6/30/2025 | BCDA | $150K | -28.2% | -36.9% | +11.3% |
| 4/23/2025 | BCDA | $250K | +29.0% | -21.5% | +24.6% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| BCDA | ▲ Buy | Open Market | 288,000 | $360K | 9/19/2025 | View on chart |
| BCDA | ▲ Buy | Open Market | 72,289 | $150K | 6/30/2025 | View on chart |
| BCDA | ▲ Buy | Open Market | 131,233 | $250K | 4/23/2025 | View on chart |
| BCDA | ▲ Buy | Grant | 111,000 | $333K | 9/3/2024 | View on chart |
| BCDA | ▲ Buy | Grant | 64,212 | $150K | 6/23/2023 | View on chart |
| BCDA | ▲ Buy | Grant | 148,809 | $250K | 12/16/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 2, 2026
BioCardia Resubmits Helix Catheter Pre-Submission to FDA
BioCardia has filed a revised de‑novo pre‑submission and resubmitted a pre‑submission to the FDA for its Helix catheter, a device intended for therapeutic and diagnostic agent delivery to the heart. The filings are part of the regulatory pathway needed before the product can reach the market. The move is a significant step in the company’s development program and could influence investor perception of the company’s progress.
BioCardia Resubmits Helix Catheter Pre-Submission to FDA. BioCardia has filed a revised de‑novo pre‑submission and resubmitted a pre‑submission to the FDA for its Helix catheter, a device intended for therapeutic and diagnostic agent delivery to the heart. The filings are part of the regulatory pathway needed before the product can reach the market. The move is a significant step in the company’s development program and could influence investor perception of the company’s progress.